Dopamine oxidation and autophagy

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Muñoz, Patricia ^a   Huenchuguala, Sandro ^a   Paris, Irmgard ^a,b   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD SANTO TOMÁS   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TUBULIN; AMINOCHROME; BETA TUBULIN; CHAPERONE; DOPAMINE; GLUTATHIONE; NEUROMELANIN; PIGMENT; UNCLASSIFIED DRUG;

AUTOPHAGY; CELL VACUOLE; CHEMICAL PROCEDURES; CONJUGATION; DOPAMINERGIC NERVE CELL; HUMAN; LYSOSOME; MICROTUBULE; NONHUMAN; ONE ELECTRON REDUCTION; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ADDUCT; PROTEIN AGGREGATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; REVIEW; TWO ELECTRON REDUCTION;

EID: 84866261026     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/920953     Document Type: Review

References (76)

1. Chaudhry F. A., Edwards R. H., Fonnum F., Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. Annual Review of Pharmacology and Toxicology 2008 48 277 301 2-s2.0-41149115776 10.1146/annurev.pharmtox.46.120604.141146
2. +-linked dopamine transport in chromaffin granule ghosts. Biochemistry 1981 20 23 6625 6629 2-s2.0-0019877702
3. Guillot T. S., Miller G. W., Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Molecular Neurobiology 2009 39 2 149 170 2-s2.0-66149143952 10.1007/s12035-009-8059-y
4. Cartier E. A., Parra L. A., Baust T. B., Quiroz M., Salazar G., Faundez V., Egaña L., Torres G. E., A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. Journal of Biological Chemistry 2010 285 3 1957 1966 2-s2.0-76249088643 10.1074/jbc.M109.054510
5. Linert W., Herlinger E., Jameson R. F., Kienzl E., Jellinger K., Youdim M. B. H., Dopamine, 6-hydroxydopamine, iron, and dioxygentheir mutual interactions and possible implication in the development of Parkinson's disease. Biochimica et Biophysica Acta 1996 1316 3 160 168 2-s2.0-0030598917 10.1016/0925-4439(96)00020-8
6. Weyler W., Hsu Y. P., Breakefield X. O., Biochemistry and genetics of monoamine oxidase. Pharmacology and Therapeutics 1990 47 3 391 417 2-s2.0-0025074333
7. Shih J. C., Grimsby J., Chen K., Baumgarten H. G., Gothert M., Molecular biology of monoamine oxidase A and B: their role in the degradation of serotonin. Handbook of Experimental Pharmacology 1997 129 Berlin, Germany Springer 655 670 Serotoninergic Neurons and 5-HT receptors in the CNS
8. Westlund K. N., Denney R. M., Rose R. M., Abell C. W., Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 1988 25 2 439 456 2-s2.0-0023942459
9. Myöhänen T. T., Schendzielorz N., Männistö P. T., Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. Journal of Neurochemistry 2010 113 6 1632 1643 2-s2.0-77953104962 10.1111/j.1471-4159.2010. 06723.x
10. Segura-Aguilar J., Metodiewa D., Welch C. J., Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochimica et Biophysica Acta 1998 1381 1 1 6 2-s2.0-0032486311 10.1016/S0304-4165(98)00036-1
11. 3+-induced neurotoxicity of dopamine: prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chemico-Biological Interactions 1989 72 3 309 324 2-s2.0-0024854643 10.1016/0009-2797(89)90006-9
12. Xu Y., Stokes A. H., Roskoski R. Jr., Vrana K. E., Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. Journal of Neuroscience Research 1998 54 691 697 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F
13. Whitehead R. E., Ferrer J. V., Javitch J. A., Justice J. B., Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. Journal of Neurochemistry 2001 76 4 1242 1251 2-s2.0-0035112815 10.1046/j.1471-4159.2001.00125.x
14. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G., Selkoe D. J., Dopamine covalently modifies and functionally inactivates parkin. Nature Medicine 2005 11 11 1214 1221 2-s2.0-30744443484 10.1038/nm1314
15. Paris I., Perez-Pastene C., Cardenas S., Iturriaga-Vasquez P., Muñoz P., Couve E., Caviedes P., Segura-Aguilar J., Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. Neurotoxicity Research 2010 18 1 82 92 2-s2.0-77956083797 10.1007/s12640-009-9148-4
16. Hastings T. G., Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. Journal of Neurochemistry 1995 64 2 919 924 2-s2.0-0028812293
17. Segura-Aguilar J., Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Biochemical and Molecular Medicine 1996 58 1 122 129 2-s2.0-0030175944 10.1006/bmme.1996.0039
18. Foppoli C., Coccia R., Cini C., Rosei M. A., Catecholamines oxidation by xanthine oxidase. Biochimica et Biophysica Acta 1997 1334 2-3 200 206 2-s2.0-0030937871 10.1016/S0304-4165(96)00093-1
19. Galzigna L., De Iuliis A., Zanatta L., Enzymatic dopamine peroxidation in substantia nigra of human brain. Clinica Chimica Acta 2000 300 1-2 131 138 2-s2.0-0033848307 10.1016/S0009-8981(00)00313-2
20. Thompson C. M., Capdevila J. H., Strobel H. W., Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. Journal of Pharmacology and Experimental Therapeutics 2000 294 3 1120 1130 2-s2.0-0033846716
21. Paris I., Dagnino-Subiabre A., Marcelain K., Bennett L. B., Caviedes P., Caviedes R., Azar C. O., Segura-Aguilar J., Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. Journal of Neurochemistry 2001 77 2 519 529 2-s2.0-0035052491 10.1046/j.1471-4159.2001.00243.x
22. Paris I., Martinez-Alvarado P., Cárdenas S., Perez-Pastene C., Graumann R., Fuentes P., Olea-Azar C., Caviedes P., Segura-Aguilar J., Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chemical Research in Toxicology 2005 18 3 415 419 2-s2.0-15344342576 10.1021/tx0497144
23. + release, tritium exchange, and spectral changes which occur during ferricyanide oxidation. Biochemistry 1968 7 9 3089 3094 2-s2.0-0014333601
24. Graham D. G., Tiffany S. M., Bell W. R. Jr., Gutknecht W. F., Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Molecular Pharmacology 1978 14 4 644 653 2-s2.0-0018148688
25. Napolitano A., Manini P., d'Ischia M., Oxidation chemistry of catecholamines and neuronal degeneration: an update. Current Medicinal Chemistry 2011 18 12 1832 1845 2-s2.0-79955679714 10.2174/092986711795496863
26. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A., Tampellini D., The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Letters 2002 510 3 216 220 2-s2.0-0037116582 10.1016/S0014-5793(01)03269-0
27. Gerlach M., Double K. L., Ben-Shachar D., Zecca L., Youdim M. B. H., Riederer P., Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotoxicity Research 2003 5 1-2 35 43 2-s2.0-0642376484 10.1007/BF03033371
28. Fasano M., Bergamasco B., Lopiano L., Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies. Journal of Neural Transmission 2006 113 6 769 774 2-s2.0-33744922127 10.1007/s00702-005- 0448-4
29. Naoi M., Maruyama W., Yi H., Yamaoka Y., Shamoto-Nagai M., Akao Y., Gerlach M., Tanaka M., Riederer P., Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component. Journal of Neurochemistry 2008 105 6 2489 2500 2-s2.0-44649136091 10.1111/j.1471-4159.2008.05329.x
30. Zhang W., Phillips K., Wielgus A. R., Liu J., Albertini A., Zucca F. A., Faust R., Qian S. Y., Miller D. S., Chignell C. F., Wilson B., Jackson-Lewis V., Przedborski S., Joset D., Loike J., Hong J. S., Sulzer D., Zecca L., Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of parkinson's disease. Neurotoxicity Research 2011 19 1 63 72 2-s2.0-78650527643 10.1007/s12640-009-9140-z
31. Norris E. H., Giasson B. I., Hodara R., Xu S., Trojanowski J. Q., Ischiropoulos H., Lee V. M. Y., Reversible inhibition of α -synuclein fibrillization by dopaminochrome-mediated conformational alterations. Journal of Biological Chemistry 2005 280 22 21212 21219 2-s2.0-20444401187 10.1074/jbc.M412621200
32. Conway K. A., Rochet J. C., Bieganski R. M., Lansbury P. T. Jr., Kinetic stabilization of the α -synuclein protofibril by a dopamine- α -synuclein adduct. Science 2001 294 5545 1346 1349 2-s2.0-0035834360 10.1126/science.1063522
33. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I., Nussbaum R. L., Mutation in the α -synuclein gene identified in families with Parkinson's disease. Science 1997 276 5321 2045 2047 2-s2.0-0030744876 10.1126/science.276.5321.2045
34. Van Laar V. S., Mishizen A. J., Cascio M., Hastings T. G., Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiology of Disease 2009 34 3 487 500 2-s2.0-67349280174 10.1016/j.nbd.2009.03.004
35. Wang X., Petrie T. G., Liu Y., Liu J., Fujioka H., Zhu X., Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. Journal of Neurochemistry 2012 121 5 830 839 10.1111/j.1471-4159.2012.07734.x
36. Baez S., Linderson Y., Segura-Aguilar J., Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochemical and Molecular Medicine 1995 54 1 12 18 2-s2.0-0028965835 10.1006/bmme.1995.1002
37. Aguirre P., Urrutia P., Tapia V., Villa M., Paris I., Segura-Aguilar J., Núñez M. T., The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 1995 25 4 795 803
38. Muñoz P., Paris I., Sanders L. H., Greenamyre J. T., Segura-Aguilar J., Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochimica et Biophysica Acta 2012 1822 7 1125 1136 10.1016/j.bbadis.2012.03.010
39. Paris I., Martinez-Alvarado P., Perez-Pastene C., Vieira M. N. N., Olea-Azar C., Raisman-Vozari R., Cardenas S., Graumann R., Caviedes P., Segura-Aguilar J., Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra. Journal of Neurochemistry 2005 92 5 1021 1032 2-s2.0-20044368007 10.1111/j.1471-4159.2004.02931.x
40. Paris I., Perez-Pastene C., Couve E., Caviedes P., LeDoux S., Segura-Aguilar J., Copper · dopamine complex induces mitochondrial autophagy preceding caspase-independent apoptotic cell death. Journal of Biological Chemistry 2009 284 20 13306 13315 2-s2.0-67649413595 10.1074/jbc.M900323200
41. Paris I., Muñoz P., Huenchuguala S., Couve E., Sanders L. H., Greenamyre J. T., Caviedes P., Segura-Aguilar J., Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicological Sciences 2011 121 2 376 388 2-s2.0-79957813128 10.1093/toxsci/kfr060
42. Arriagada C., Paris I., Sanchez de las Matas M. J., Martinez-Alvarado P., Cardenas S., Castañeda P., Graumann R., Perez-Pastene C., Olea-Azar C., Couve E., Herrero M. T., Caviedes P., Segura-Aguilar J., On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiology of Disease 2004 16 2 468 477 2-s2.0-2942536124 10.1016/j.nbd.2004. 03.014
43. Fuentes P., Paris I., Nassif M., Caviedes P., Segura-Aguilar J., Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell linean experimental cell model for dopamine toxicity studies. Chemical Research in Toxicology 2007 20 5 776 783 2-s2.0-34250702138 10.1021/tx600325u
44. Díaz-Véliz G., Paris I., Mora S., Raisman-Vozari R., Segura-Aguilar J., Copper neurotoxicity in rat substantia Nigra and striatum is dependent on DT-diaphorase inhibition. Chemical Research in Toxicology 2008 21 6 1180 1185 2-s2.0-47049090944 10.1021/tx8001143
45. Muñoz P., Huenchuguala S., Paris I., Cuevas C., Villa M., Caviedes P., Segura-Aguilar J., Tizabi Y., Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease. Neurotoxicity Research 2012 22 2 177 180 10.1007/s12640-012-9326-7
46. Lozano J., Muñoz P., Nore B. F., Ledoux S., Segura-Aguilar J., Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chemical Research in Toxicology 2010 23 9 1492 1496 2-s2.0-77956914561 10.1021/tx100182a
47. Segura-Aguilar J., Cardenas S., Riveros A., Fuentes-Bravo P., Lozano J., Graumann R., Paris I., Nassif M., Caviedes P., DT-diaphorase prevents the formation of alpha-synuclein adducts with aminochrome. Society for Neuroscience 2006 824, article 17
48. Cardenas S. P., Perez-Pastene C., Couve E., Segura-Aguilar J., The DT-diaphorase prevents the aggregation of a-synuclein induced by aminochrome. Neurotoxicity Research 2008 13, article 136
49. Schultzberg M., Segura-Aguilar J., Lind C., Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 1988 27 3 763 776 2-s2.0-0024259752
50. Segura-Aguilar J., Baez S., Widersten M., Welch C. J., Mannervik B., Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. Journal of Biological Chemistry 1997 272 9 5727 5731 2-s2.0-0031041078 10.1074/jbc.272.9.5727
51. Baez S., Segura-Aguilar J., Widersten M., Johansson A. S., Mannervik B., Glutathione transferases catalyse the detoxication of oxidized metabolites (o -quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochemical Journal 1997 324 1 25 28 2-s2.0-0030967073
52. Shen X. M., Xia B., Wrona M. Z., Dryhurst G., Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chemical Research in Toxicology 1996 9 7 1117 1126 2-s2.0-0029967920 10.1021/tx960052v
53. Cheng F. C., Kuo J. S., Chia L. G., Elevated 5-S-cysteinyldopamine/ homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. Journal of Neural Transmission 1996 103 4 433 446 2-s2.0-0029878379
54. Rosengren E., Linder-Eliasson E., Carlsson A., Detection of 5-S-cysteinyldopamine in human brain. Journal of Neural Transmission 1985 63 3-4 247 253 2-s2.0-0021849271
55. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., Rosengren E., The neuromelanin of the human substantia nigra. Biochimica et Biophysica Acta 1991 1097 2 152 160 2-s2.0-0025734502 10.1016/0925-4439(91)90100-N
56. Dagnino-Subiabre A., Cassels B. K., Baez S., Johansson A. S., Mannervik B., Segura-Aguilar J., Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o -quinones. Biochemical and Biophysical Research Communications 2000 274 1 32 36 2-s2.0-0033930678 10.1006/bbrc.2000.3087
57. Ito S., Kato T., Maruta K., Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 1984 311 1 154 159 2-s2.0-0021674392
58. Matsui Y., Kyoi S., Takagi H., Hsu C. P., Hariharan N., Ago T., Vatner S. F., Sadoshima J., Molecular mechanisms and physiological significance of autophagy during myocardial ischemia and reperfusion. Autophagy 2008 4 4 409 415 2-s2.0-43949114864
59. Tettamanti G., Saló E., González-Estévez C., Felix D. A., Grimaldi A., de Eguileor M., Autophagy in invertebrates: insights into development, regeneration and body remodeling. Current Pharmaceutical Design 2008 14 2 116 125 2-s2.0-38949181943 10.2174/138161208783378716
60. Kuma A., Mizushima N., Physiological role of autophagy as an intracellular recycling system: with an emphasis on nutrient metabolism. Seminars in Cell and Developmental Biology 2010 21 7 683 690 2-s2.0-77956172813 10.1016/j.semcdb.2010.03.002
61. Lynch-Day M. A., Mao K., Wang K., Zhao M., Klionsky D. J., The role of autophagy in Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2012 2 4 1 13 a009357
62. Vogiatzi T., Xilouri M., Vekrellis K., Stefanis L., Wild type α -synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. Journal of Biological Chemistry 2008 283 35 23542 23556 2-s2.0-53049098471 10.1074/jbc.M801992200
63. Xilouri M., Vogiatzi T., Vekrellis K., Park D., Stefanis L., Abberant α -synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 2009 4 5 2-s2.0-65849127844 10.1371/journal.pone.0005515 e5515
64. Cuervo A. M., Stafanis L., Fredenburg R., Lansbury P. T. Jr., Sulzer D., Impaired degradation of mutant α -synuclein by chaperone-mediated autophagy. Science 2004 305 5688 1292 1295 2-s2.0-4344659685 10.1126/science.1101738
65. Chinta S. J., Mallajosyula J. K., Rane A., Andersen J. K., Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neuroscience Letters 2010 486 3 235 239 2-s2.0-78049383132 10.1016/j.neulet.2010.09.061
66. Winslow A. R., Chen C. W., Corrochano S., Acevedo-Arozena A., Gordon D. E., Peden A. A., Lichtenberg M., Menzies F. M., Ravikumar B., Imarisio S., Brown S., O'Kane C. J., Rubinsztein D. C., α -Synuclein impairs macroautophagy: implications for Parkinson's disease. Journal of Cell Biology 2010 190 6 1023 1037 2-s2.0-77957189194 10.1083/jcb.201003122
67. Kabuta T., Furuta A., Aoki S., Furuta K., Wada K., Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. Journal of Biological Chemistry 2008 283 35 23731 23738 2-s2.0-53049101345 10.1074/jbc.M801918200
68. Narendra D., Tanaka A., Suen D. F., Youle R. J., Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Journal of Cell Biology 2008 183 5 795 803 2-s2.0-58149314211 10.1083/jcb.200809125
69. McCoy M. K., Cookson M. R., DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011 7 5 531 532 2-s2.0-79955701611 10.4161/auto.7.5.14684
70. Plowey E. D., Cherra S. J. III, Liu Y. J., Chu C. T., Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. Journal of Neurochemistry 2008 105 3 1048 1056 2-s2.0-39549117093 10.1111/j.1471-4159.2008.05217.x
71. Dadakhujaev S., Noh H. S., Jung E. J., Cha J. Y., Baek S. M., Ha J. H., Kim D. R., Autophagy protects the rotenone-induced cell death in α -synuclein overexpressing SH-SY5Y cells. Neuroscience Letters 2010 472 1 47 52 2-s2.0-77149132129 10.1016/j.neulet.2010.01.053
72. Xiong N., Jia M., Chen C., Xiong J., Zhang Z., Huang J., Hou L., Yang H., Cao X., Liang Z., Sun S., Lin Z., Wang T., Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience 2011 199 292 302 10.1016/j.neuroscience.2011.10.031
73. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A. C., Mazzulli J., Mosharov E. V., Hodara R., Fredenburg R., Wu D. C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P. T. Jr., Sulzer D., Cuervo A. M., Dopamine-modified α -synuclein blocks chaperone-mediated autophagy. Journal of Clinical Investigation 2008 118 2 777 778 2-s2.0-38849174979 10.1172/JCI32806
74. Köchl R., Hu X. W., Chan E. Y. W., Tooze S. A., Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic 2006 7 2 129 145 2-s2.0-33645120442 10.1111/j.1600-0854.2005.00368.x
75. Jahreiss L., Menzies F. M., Rubinsztein D. C., The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic 2008 9 4 574 587 2-s2.0-40449139980 10.1111/j.1600-0854.2008.00701.x
76. Zafar K. S., Siegel D., Ross D., A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Molecular Pharmacology 2006 70 3 1079 1086 2-s2.0-33747624165 10.1124/mol.106.024703